1. Introduction {#s0005}
===============

Intimate partner violence (IPV) is psychological, physical, or sexual abuse occurring in an intimate relationship ([@bb0080]). Centers for Disease Control (CDC) estimates from 2011 suggest that IPV is highly prevalent within US society, with 19% of women experiencing rape within their lifetimes, and 44% of women experiencing other sexual violence ([@bb0040]). IPV has been identified as an etiological risk factor in the development of numerous physical and psychological comorbidities ([@bb0045]), and accounts for significant healthcare expenditure annually ([@bb0150]). Thus, healthcare providers are poised to be powerful resources for women by addressing safety concerns and connecting women to resources, with the aim of preventing future violence and reducing morbidity and mortality.

While numerous organizations have issued recommendations for IPV screening, such recommendations, until recently, have not been codified at the federal level. Recognizing the substantial impact of IPV on health, the Institute of Medicine (IOM) determined in 2011 that a substantial preventive service deficit exists in the detection of and intervention in IPV-related morbidity and mortality. Accordingly, the IOM recommended that all women should be screened and counseled for IPV in the healthcare setting, stating "screening for risk of abuse is central to women\'s safety" ([@bb0095]). In 2013, the United States Preventive Services Task Force (USPSTF) recommended that healthcare providers screen all women of reproductive age (18--46) for lifetime exposure to IPV, and provide appropriate follow-up ([@bb0130]).

Numerous organizations, including Futures Without Violence, the American Medical Association (AMA), and the American College of Obstetricians and Gynecologists (ACOG), have proposed best-practice guidelines for IPV screening, as well as recommendations for counseling following disclosure. These recommendations address the context and content of screening and provide suggestions for navigating follow-up discussions if a woman discloses abuse ([@bb0080], [@bb0010], [@bb0005]).

Evidence-based guidelines regarding the context of IPV screening focus on periodic screening that addresses recent and past IPV exposure. Research shows that women who were previously exposed to IPV are more likely to be re-exposed in the future, and thus comprise a high-risk population ([@bb0110]). Additionally, women should be screened in private in order to maximize disclosure, and more importantly, decrease the risk of retaliation should their partner become aware of the disclosure ([@bb0080], [@bb0010], [@bb0005]).

Guidelines regarding the content of IPV screening and counseling discussions include both discussion topics and provider interventions ([@bb0015]). Given the sensitive nature of IPV-related discussions, the healthcare provider\'s initial response has potential to influence further discussion as well as the patient\'s course of action once she leaves the office ([@bb0140], [@bb0105]). Disclosure of IPV warrants an immediate in-depth conversation. The provider\'s initial response should focus on validation of the patient\'s experience, thus establishing a sense of solidarity against IPV ([@bb0015]). Further discussion should consist of assessing the safety of the patient and other household members, the pattern and severity of abuse, and should include development of a safety plan if abusive behavior escalates ([@bb0080], [@bb0005], [@bb0015]). Likewise, the provider should assess the impact IPV is having on the woman\'s physical health, mental health, and interpersonal relationships to determine how best to approach further discussion and intervention ([@bb0080], [@bb0010], [@bb0005]).

To date, relatively little research has addressed the nature of the discussions that take place following screening or patient perceptions of these encounters; however, women who discuss IPV with their healthcare providers are more likely to pursue other safety measures, such as contacting community-based domestic violence services ([@bb0025], [@bb0065]). Barriers to discussing IPV with patients commonly cited by healthcare providers include time constraints, provider discomfort with IPV screening questions, and lack of provider knowledge of referral resources ([@bb0115]). Sutherland et al., in 2014 found that, of clinicians who screened patients for IPV, 13% did not document any follow-up discussion, and the vast majority (81.5%) did not offer an action-oriented response, such as offering a follow-up appointment or making a referral to domestic violence services ([@bb0170]).

Similarly, providers historically have expressed concern that screening for IPV may harm the patient-provider relationship; however, these concerns have been largely unfounded in analysis of real-world screening programs ([@bb0145]). Patients who have been exposed to IPV tend to view counseling discussions with their healthcare providers as a strategic response ([@bb0175]). Indeed, patients who receive preventive services such as IPV screening are more likely to report being satisfied with the encounter ([@bb0190]).

While many previous studies have addressed screening rates, very little data exists regarding the content of discussions that follow screening. Likewise, little data exists regarding the acceptability of IPV-related discussions from the patient\'s perspective---especially those previously exposed to IPV---as most studies focus on provider-perceived barriers to screening. This study seeks to examine screening rates following the 2013 USPSTF recommendation for universal IPV screening, as well as to add insight into the context and content of the discussion that takes place surrounding IPV screening. Finally, we seek to provide a more robust idea of the opinions of women regarding IPV-related discussions. In accordance with guidelines proposed by Futures Without Violence, as well as recommendations by AMA and ACOG, we developed a survey to examine the context and content of IPV-related discussions in the healthcare setting, and to characterize patients\' comfort and satisfaction with the encounter. The conceptual framework of the study is included in [Fig. 1](#f0005){ref-type="fig"}. We underscore the importance of characterizing these clinical encounters, so as to better understand the areas for improvement in healthcare provider-based preventive screening, counseling, and intervention for IPV-exposed women.Fig. 1Conceptual framework for IPV discussions in clinical setting. Data collected May 2014--January 2015, Central PA.Fig. 1

2. Methods {#s0010}
==========

Surveys were administered as part of a longitudinal study of women\'s health issues in a population with lifetime exposure to IPV. Inclusion criteria included: 1) female gender, 2) age 18--64, 3) a healthcare appointment in the preceding year, and 4) history of lifetime IPV, measured by a modified HARK screening instrument ([@bb0160]) (The original language of the HARK instrument asks women "Within the last year, have you \[been exposed to "X"\]?" We modified this to form a two-level question in which participants were asked "Within your lifetime, have you \[been exposed to "X"\]." If the response was affirmative, they were then asked about exposure in the preceding year). Consent to participate in this research study was obtained from all participants. Study documents and protocols were reviewed and approved by the Institutional Review Board of the Pennsylvania State University. A Certificate of Confidentiality was obtained from the National Institutes of Mental Health (CC-MH-12-204) prior to the conduct of this research.

The primary source for recruitment was the Penn State Ambulatory Research Network (PSARN), a group of outpatient primary care clinics in Central Pennsylvania affiliated with the Penn State Health Milton S. Hershey Medical Center. PSARN-associated clinics are comprised of approximately 125 providers, and encompass the specialties of Family Medicine, Internal Medicine, and Pediatrics. The mission of PSARN is to provide a platform from which to conduct primary care research.

From 24,338 eligible women with an appointment at a PSARN facility in the 12 months prior to recruitment, a randomized, rurality-stratified subsample of 2500 women was constructed. Stratification based on rurality was performed to over-sample rural residents, as the parent study was designed to examine strategies and mental health outcomes in rural women exposed to IPV. These women were sent screening questionnaires with a \$2 incentive. Participants had the option of completing screening questionnaires online, by phone, or by mail. Participants were considered to screen positive for IPV exposure if they reported any lifetime exposure to emotional, physical, or sexual abuse on the modified HARK instrument. 1191 women responded to the screening questionnaire, of whom 500 reported IPV exposure. These women were invited to complete a baseline survey via mail, phone, or online survey. These women received a \$25 gift card as compensation. 271 women from PSARN completed the baseline survey.

This sample was augmented by recruitment from 26 Pennsylvania women\'s shelters, which were non-profit organizations with the mission of assisting women with housing as well as providing crisis and counseling services for women exposed to IPV. Flyers posted in these shelters advertised the opportunity to participate in this study. Screening questionnaires were returned by 73 women, of whom 60 reported lifetime IPV exposure. 39 women completed the baseline survey. In total, 310 women completed the baseline survey. Recruitment, screening, and completion of baseline surveys took place from May 2013--January 2014.

Participants were again contacted one year later to complete a follow-up survey. Of the 310 individuals who completed the baseline survey, 266 completed follow-up surveys. 250 women reported having a healthcare visit in the year since baseline survey completion. These women comprised our analytic subsample. 222 were recruited from PSARN and 28 were recruited from women\'s shelters. Data collection for the current analysis took place from May 2014--January 2015.

2.1. Measures {#s0015}
-------------

Demographic information including age and race was obtained from questions adapted from standardized surveys already used in this population, such as the Central Pennsylvania Women\'s Health Study (CePAWHS) ([@bb0195]).

To the authors\' knowledge, there are no validated survey instruments regarding patient-reported content and context of IPV-related discussions. To evaluate the context and content of IPV screening and counseling discussions, we developed and pretested a set of questions using evidence-based guidelines from the USPSTF, the American Medical Association, Futures Without Violence, and the American College of Obstetricians and Gynecologists, and informed by prior research ([@bb0010], [@bb0120], [@bb0180], [@bb0020], [@bb0055], [@bb0090]). Pretesting was conducted by administering the survey to 10 individuals of reproductive age, who offered feedback regarding the readability of the questions, the adequacy of the answer options, and the length of the survey. Feedback was incorporated into new survey drafts.

The context of the screening encounter was determined to be the presence of other individuals in the room at the time of IPV screening. Content questions consisted of selecting discussion topics, education-based outcomes, and action-based outcomes from a list generated from guidelines published by Futures Without Violence, ACOG, and the AMA. The checklist of potential responses can be seen in the original survey document (Appendix). Participants had an option to add free-text responses, which were reviewed by investigators and recoded either as a listed option or added as a separate intervention in the descriptive statistics.

Patient perceptions centered on privacy concerns, unshared information, and satisfaction and comfort levels. Satisfaction and comfort were determined on a 5-point, Likert-type scale, with language modified from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Satisfaction Survey ([@bb0090]). Participants were subsequently asked if there was anything they wanted to discuss with their provider but were not able to. If they responded affirmatively, they were asked what they would have liked to discuss and why they felt they were unable to do so. Free-text responses were recorded. If women reported that they did not have an IPV-related discussion with their provider, a follow-up question was asked: "would you have liked to talk to a healthcare provider about domestic violence or whether you feel safe at home?"

2.2. Statistical analysis {#s0020}
-------------------------

Frequencies for demographics, screening rates, and guideline-concordant discussion topics and interventions were developed for the full population. Analyses of questions regarding context, content, and patient perceptions were limited to women who reported that screening or IPV disclosure had occurred in a healthcare visit within the past year. As the purpose of this analysis was largely to obtain descriptive measures, we did not control for potential covariates, interactions, or missing data.

Study data were collected and managed using REDCap electronic data capture tools hosted at Pennsylvania State University. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies ([@bb0085]).

The data analysis for this paper was generated using SAS software, Version 9.3 of the SAS System ([@bb0155]). All analyses were performed from October 2014--March 2015.

3. Results {#s0025}
==========

3.1. Demographics {#s0030}
-----------------

As shown in [Table 1](#t0005){ref-type="table"}, of 253 IPV-exposed women, mean age was 43.4 years (± 12.4). 54.2% of the population was of reproductive age (18--46). 91% of the sample was White, non-Hispanic, with 3% Black, 1% Asian, and 1% other. 88% were recruited from clinic sites, and 11% from women\'s shelters. 52% were exposed to IPV within the past year.Table 1Demographic information. Data collected May 2014--January 2015, Central PA.Table 1Mean age43.5 ± 12.4N%Age Reproductive age (18--46)13754.2% Greater than reproductive age (\> 46)11344.7%Race White, non-Hispanic22991% Black72.8% Asian20.8% Other249%Recruitment site PSARN22288% Women\'s shelter2911%Screening status Screened9839% Not screened15561%IPV exposure Past-year5221% Lifetime20179%

3.2. Screening rates {#s0035}
--------------------

Of 253 women, 39% (N = 98) reported discussing IPV with their healthcare providers. Eight percent of women who discussed IPV with their provider reported initiating the discussion without being asked.

3.3. Screening context {#s0040}
----------------------

As shown in [Table 2](#t0010){ref-type="table"}, during IPV-related discussions with their healthcare providers, 10% reported that someone else was in the room. None of the other individuals in the room were spouses or partners.Table 2Screening context, content, and patient perceptions. Data collected May 2014--January 2015, Central PA.Table 2DomainN (%)Screening contextOther individual in room Yes10 (10) No88 (90)Screening contentCurrently concerned with IPV7 (7)Discussion topics Patient\'s concern about situation32 (33) Patient\'s emotional health20 (20) Patient\'s physical health11 (11) Safety assessment19 (19) Nature of abuse16 (16) Partner\'s substance abuse9 (9) Effects on relationships with friends/family9 (9) Effects on children5 (5)Number of guideline-concordant discussion topics used None29 (30) One42 (42) Multiple27 (28)Outcomes Provided information about resources22 (22) Validated patient\'s experience18 (18) Developed/discussed a safety plan14 (14) Prescribed medication14 (14) Scheduled follow-up14 (14) Scheduled mental health appointment5 (5) Provided information about IPV3 (3) Provided information for social or community services2 (2) Contacted law enforcement1 (1)Number of guideline-concordant responses offered None27 (28) One58 (59) Multiple13 (13)Patient perceptionsSatisfaction in discussing IPV with provider Extremely satisfied28 (29) Very satisfied27 (28) Somewhat satisfied12 (12) Somewhat dissatisfied1 (1) Very dissatisfied0 (0)Comfort in discussing IPV with provider Extremely comfortable24 (25) Very comfortable26 (27) Somewhat comfortable9 (9) Somewhat uncomfortable5 (5) Very uncomfortable2 (2)Did not discuss IPV with provider (N = 155), but would have liked to10 (4)

3.4. Screening content {#s0045}
----------------------

As shown in [Table 2](#t0010){ref-type="table"}, of the 98 women who discussed IPV with their healthcare provider in the past year, 7% told their healthcare provider that they were currently concerned about domestic violence. Guideline-concordant discussion topics included: patient\'s concern about situation (33%), patient\'s emotional (20%) or physical (11%) health, safety assessment (19%), nature of abuse (16%), partner\'s substance abuse (9%), effects on friends/family (9%), and children (5%). Composite analyses of these conversations showed that 30% of women did not have a discussion composed of any guideline-concordant topics, 42% of women had a discussion encompassing one guideline-concordant topic, and 28% of women had a discussion including more than one guideline-concordant topic.

Guideline-concordant outcomes of these discussions included providing information about available resources (22%), validation of the patient\'s experience (18%), development of a safety plan (14%), providing prescription medication (14%), scheduling a follow-up appointment (14%), scheduling a mental health appointment (5%), providing information regarding IPV (3%), providing contact information for social or domestic violence services (2%), and contacting law enforcement (1%). Composite analyses of these interactions showed that 28% of IPV-related discussions did not result in a guideline-concordant intervention, 58% resulted in one guideline-concordant intervention, and 14% resulted in multiple guideline-concordant interventions.

3.5. Patient perceptions {#s0050}
------------------------

Of all women screened for IPV, 28.5% reported being "extremely satisfied" with their discussion with their healthcare provider, 27.5% "very satisfied," 12% "somewhat satisfied", and 1% "somewhat dissatisfied." The non-response rate for this question was 31%. Likewise, 25% reported being "extremely comfortable" discussing IPV with their healthcare provider, 27% "very comfortable," 9% "somewhat comfortable," 5% "somewhat uncomfortable," and 2% "very uncomfortable." The non-response rate for this question was 33%. Of women who did not discuss IPV with their healthcare provider (N = 155), 4% would have liked to have talked about IPV with their providers, but did not feel they had the chance. Two participants offered free-text responses for why they felt they were unable to discuss their exposure to IPV with their healthcare provider. One participant related that she felt there was not adequate time, and the other stated, "I couldn\'t talk to her and get her to understand what was really going on." No women reported having concerns about confidentiality associated with these clinical encounters. Two women had concerns they felt were not addressed in the conversation with their provider.

4. Discussion {#s0055}
=============

This study adds essential knowledge to the current literature regarding universal IPV screening by 1) quantifying screening rates subsequent to the 2013 USPSTF recommendation, 2) exploring content of IPV-related discussions, and 3) investigating the acceptability of IPV screening in a subset of women previously exposed to IPV.

4.1. Screening rates post-2013 USPSTF recommendation {#s0060}
----------------------------------------------------

One of the primary aims of this study was to examine the rates of IPV screening subsequent to the 2013 USPSTF recommendation for universal screening of reproductive-aged women. Despite evidence that women who have experienced IPV in the past are more likely to experience it again ([@bb0110]), IPV screening in our sample remained low at 39%.

Previous studies have examined the rationale behind low rates of screening from providers\' perspectives, with cited barriers including lack of time ([@bb0070]), lack of knowledge regarding community resources, feelings of powerlessness ([@bb0070], [@bb0075]), underestimation of the effects of IPV ([@bb0075]), and fear of damaging rapport with patients ([@bb0075]). Our data show that despite national efforts in the US supporting universal IPV screening ([@bb0130], [@bb0015], [@bb0035]), rates of screening remain unacceptably low.

Previous research shows that educating providers about the prevalence of IPV and providing validated methods of screening increases screening rates ([@bb0185]). Beyond provider education, system-wide support for IPV screening---including collaboration between physicians, nurses, staff, and social workers---has been shown to improve attitudes toward screening ([@bb0050]). Thus, system-wide supports should be implemented to ensure that healthcare providers have the resources necessary to address these sensitive issues as they arise.

4.2. Screening context and content {#s0065}
----------------------------------

Another primary aim of this study was to develop further insight into the context and content of IPV screening and counseling discussions. We found that the vast majority of respondents were screened in private, and those who were not alone at the time of screening were accompanied by a nurse or family member other than a partner or spouse (a young child, for example). Therefore, providers who did perform screening appeared to do so with privacy considerations in mind.

Regarding the content of IPV-related discussions, little research has explored the outcomes (particularly non-tangible outcomes) of IPV-related discussions in the healthcare setting. In their 2015 Cochrane review, O\'Doherty et al. reveal that universal screening, while resulting in increased IPV detection, resulted inconsistently in increased referral to services ([@bb0135]). Our data reflect that guideline-concordant discussion topics were employed in nearly 70% of patient encounters where screening occurred, and guideline-concordant interventions were employed in 72% of encounters. These data suggest that even though screening rates may not have changed appreciably, physicians who *do* screen frequently respond with guideline-concordant topics/interventions.

These data must be approached cautiously. While it is heartening that providers who screen pursue appropriate discussion topics and interventions, it is of paramount importance to remember that only 39% of providers performed IPV screening. Greater efforts must be made to remove provider-perceived barriers to screening.

The CDC\'s National Intimate Partner and Sexual Violence Survey addresses the outstanding need for integration of domestic violence services into the healthcare response to IPV disclosure, stating "the health care system\'s response must be strengthened and better coordinated for \[...\] survivors to help navigate the health care system and access needed services and resources in the short and long term" ([@bb0030]).

4.3. Patient perceptions of IPV screening and counseling discussions {#s0070}
--------------------------------------------------------------------

The third aim of this study was to examine patient perceptions of IPV screening. Despite low screening rates, we found that the majority of women who participated in IPV-related discussions felt comfortable discussing IPV with their providers, and that, among women who did not have the opportunity to discuss IPV, some would have liked to have had this discussion.

Patient acceptance of IPV screening in the healthcare setting has been reported in the international literature, with studies in Germany, New Zealand, and Ireland reporting acceptability rates \> 90% ([@bb0165], [@bb0100], [@bb0125]). Likewise, US studies have shown similar figures when addressing IPV screening among pregnant women ([@bb0145]). To the authors\' knowledge, however, this is the first study addressing the acceptability of IPV screening in women exposed to IPV. While further investigation into factors influencing the acceptability of IPV-related discussions in IPV-exposed women is warranted, our data should encourage providers who may be reluctant to discuss IPV in the clinical setting ([@bb0060]).

4.4. Limitations and strengths {#s0075}
------------------------------

Limitations of this study include the fact that data obtained regarding clinical encounters rely on recollection of information that may be as distant as one year in the past. Likewise, while much of our survey instrument was based on well-validated instruments (CePAWHS, HARK, HCAHPS, etc.) ([@bb0160], [@bb0195], [@bb0090]), additional questions were formulated specifically for the purposes of obtaining information regarding the context and content of IPV screening and counseling. The language of these sections of the survey has no prior validation. Additionally, as our sample was comprised of women who had attended a healthcare appointment in the past year, some of whom were using services of a local women\'s shelter, this group may display greater help-seeking behavior than other women who have experienced IPV, possibly influencing disclosure rates and attitudes toward medical professionals. Also, our sample was comprised of over 90% white, non-Hispanic participants. While this distribution is representative of central Pennsylvania and the catchment area of our outpatient primary clinics, it is not generalizable to other locales. Finally, our study was geographically limited. Screening practices of providers may be influenced by local context, such as the availability of referral resources, the perceived support for screening and counseling in healthcare practices, and regional culture. Thus, the experiences of the patients in our sample may not be representative of patients who are screened in a different region or practice setting.

Strengths of this study include contributing to a relatively small repository of data regarding IPV screening rates subsequent to the 2013 USPSTF recommendation. Additionally, this study is the first, to our knowledge, to measure the context and content of IPV screening and counseling encounters in accordance with best practice guidelines, and to examine acceptability of IPV screening in a high-risk population of women previously exposed to IPV.

5. Conclusions {#s0080}
==============

Our data suggest that further efforts are necessary to ensure that screening and counseling discussions comprise a meaningful part of women\'s healthcare. Focus should remain on keeping providers abreast of resources within their communities for women who have been exposed to IPV, while systems- and community-based support must be in place in the event of a disclosure, as IPV screening that does not result in meaningful follow-up discussion and intervention does little to improve the lives of women exposed to IPV.
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